Oppenheimer

July signed off with a bang, in what turned out to be the stock market's best month since November 2020. Better-than-anticipated Q2 earnings from some of ...

Overall, Kim thinks the stock has some way to go, and by some way, we mean 159% of upside. If Kim’s target looks optimistic, then up against his colleagues’ forecast, it appears conservative; at $24.40 the average target makes room for 12-month gains of 386%. ( See Aldeyra stock forecast on TipRanks) For the former indication, the company only recently released data from a double-masked, vehicle-controlled crossover clinical trial in which the drug met its end goals. There’s also ADX-2191, being developed to prevent proliferative vitreoretinopathy and for the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. As Aldeyra reaches potential commercialization in the 2023 timeframe, we anticipate the shares could experience significant re-rating.” Rather than directly inhibiting or activating single protein targets, the company’s method is to discover pharmaceuticals that modulate immunological systems, with the aim of optimizing multiple pathways while at the same time keeping toxicity to a minimum. These comments form the basis of Kotowski’s Outperform (i.e., Buy) rating and $70 price target. We’ll start off with global alternative asset management firm Carlyle Group. Since its foundation in 1987, the company has turned into one of the world’s most successful alternative asset managers, boasting assets under management (AUM) totaling $376 billion. From a purely technical perspective, Oppenheimer’s Head of Technical Analysis Ari Wald sees reasons to believe the surge has legs. It was a strong quarter in terms of earnings and investment performance. July signed off with a bang, in what turned out to be the stock market’s best month since November 2020. Overall, we maintain our view that the index is on the road to recovery and think 4,600 (~12% upside) is reasonable by year-end.”

PRNewswire/ -- Oppenheimer & Co. Inc. ("Oppenheimer") – a leading wealth manager, investment bank, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) –...

I look forward to becoming part of the Oppenheimer family and partnering with the team." Oppenheimer & Co. Inc. Prior to joining Oppenheimer, Mr. Watkins was with KPMG since 2003, spending the bulk of his time in their New York Financial Services Audit Practice, where he launched his career and rose through the ranks before becoming a partner in 2015. "Brad is an experienced leader with a strong background across the financial services industry," Mr. Lowenthal comments. As a member of the Management Committee, Mr. Watkins will report to Albert G. Lowenthal, Chairman and CEO. Oppenheimer & Co. Inc.